April 2024 Question
CHEST Curriculum Pathway for Lung Cancer: Which of the following is the preferred agent for treating EGFR mutant non-small cell lung cancer (NSCLC) after complete surgical resection of stage II disease?
The American College of Chest Physicians is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research, and team-based care.
[fa icon="phone"] +1 (224) 521-9800
[fa icon="envelope"] helpteam@chestnet.org
[fa icon="home"] 2595 Patriot Blvd, Glenview IL 60026
Copyright 2024 © American College of Chest Physicians ®